Recursion Pharmaceuticals, a US-based biotech spinout from University of Utah, obtained $60m in an oversubscribed series B round on Tuesday featuring Abu Dhabi’s sovereign wealth fund Mubadala Investment.
The round was led by venture capital fund Data Collective, and was backed by Lead Lux Capital, Obvious Ventures, Advantage Capital, Felicis Ventures, Epic Ventures, AME Ventures, Menlo Ventures, CRV, Two Sigma Investments and High-Value Angel Investors.
Recursion hopes its machine-learning based drug discovery technology will dramatically increase the number of remedies…
